Panel Recommends Schering's Saphris; Safety Profile Could Provide Niche
Executive Summary
The atypical antipsychotic market should soon be seeing competition from a new entry with a novel formulation and a more attractive safety profile, after an FDA advisory committee voted strongly in favor of Schering Plough's Saphris (asenapine) for acute schizophrenia and bipolar disorder
You may also be interested in...
Lurasidone Beats Placebo In Phase III, But Zyprexa Arm Could Confound
Dainippon Sumitomo Pharma Co. has enough positive pivotal trials for its planned 2010 NDA filing for the atypical antipsychotic lurasidone, but newly released data from one of those trials reveal a discrepancy in the efficacy results that could be a hurdle at FDA.
Lurasidone Beats Placebo In Phase III, But Zyprexa Arm Could Confound
Dainippon Sumitomo Pharma Co. has enough positive pivotal trials for its planned 2010 NDA filing for the atypical antipsychotic lurasidone, but newly released data from one of those trials reveal a discrepancy in the efficacy results that could be a hurdle at FDA.
Dainippon's Phase III Trial Shows Lurasidone Advantage Over Placebo, But Not Against Zyprexa
Like the newly-approved Saphris, lurasidone showed little impact on weight and other metabolic parameters in second Phase III PEARL study. The Japanese firm is going for a safety, not efficacy, entry point into the atypical class.